Ann: CLINUVEL Newsletter II - April 2023, page-2

Very good newsletter, lots in the pipeline and happy to hold this for the long term. Nothing really changes SP wise, continual manipulations with algo trades determined to sell at the lowest possible price to maintain the weak SP unlike most investors trying to get the best price possible when selling. Interesting snippet from this link on nasdaq.com https://www.nasdaq.com/articles/wilsons-maintains-clinuvel-pharmaceuticals-asx:cuv-overweight-recommendation "Total shares owned by institutions increased in the last three months by 2.88% to 2,381K shares." Also thought the 38 page CUV ASX release from nearly one year ago on 20/05/22 about 'becoming a substantial holder' contained really intriguing stuff. Strange games ongoing, even Clinuvel pointing out in the newsletter that the price is below analyst targets of $37.3 to $23.21. Well guess what guys, companies in that situation with the massive cash reserves and firepower of Clinuvel would probably implement a share buyback - even just 10-20 Million Dollars - to show support to holders and take advantage of the low price to reduce the number of shares on issue for everlasting benefits and making the company a more attractive investment opportunity. Very few companies have the resources to do this like Clinuvel does.

All IMO DYOR